Zoledronic acid treatment in children with osteogenesis imperfecta

Hormone Research in Paediatrics

Volumn 75, Issue 5, 2011, Pages 346-353

  Vuorimies, Ilkka ^a   Toiviainen Salo, Sanna ^b   Hero, Matti ^a   Mäkitie, Outi ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Bisphosphonates; Bone mineral density; Bone turnover; Fracture; Osteogenesis imperfecta

Indexed keywords

CALCIUM; COLECALCIFEROL; PARATHYROID HORMONE; PHOSPHATE; ZOLEDRONIC ACID;

ADOLESCENT; ARTICLE; BONE DENSITOMETRY; BONE MINERAL; BONE PAIN; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ARTICLE; COMPRESSION FRACTURE; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FRACTURE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; LONG BONE; LUMBAR SPINE; MALE; MUSCLE TREMOR; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PEDIATRICS; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR;

ADOLESCENT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; IMIDAZOLES; INFANT; LUMBAR VERTEBRAE; MALE; OSTEOGENESIS IMPERFECTA; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 79955687595     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000323368     Document Type: Article

References (31)

1. Sillence DO, Senn A, Danks DM: Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16: 101-116. (Pubitemid 9164903)
2. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ: Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000; 15: 1650-1658. (Pubitemid 30666219)
3. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R: Osteogenesis imperfect type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002; 17: 30-38. (Pubitemid 33150994)
4. Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, Roughley PJ, Glorieux FH: Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002; 31: 12-18. (Pubitemid 34754419)
5. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM: Classification of osteogenesis imperfecta revisited. Eur J Med Genet 2010; 53: 1-5.
6. Arikoski P, Silverwood B, Tillmann V, Bishop NJ: Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 2004; 34: 539-546. (Pubitemid 38314918)
7. Astrom E, Soderhall S: Beneficial effect of long-term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86: 356-364. (Pubitemid 34478233)
8. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952. (Pubitemid 28455096)
9. Lee YS, Low SL, Lim LA, Loke KY: Cyclic pamidronate infusion improves bone mineralization and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001; 160: 641-644.
10. Rauch F, Plotkin H, Zeitlin L, Glorieux FH: Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003; 18: 610-614. (Pubitemid 36899310)
11. Zacharin M, Kanumakala S: Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. J Pediatr Endocrinol 2004; 17: 1511-1517. (Pubitemid 39497003)
12. Lowing K, Astrom E, Oscarsson KA, Soderhall S, Eliasson AC: Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. Acta Paediatr 2007; 96: 1180-1183. (Pubitemid 47106528)
13. Zeitlin L, Rauch F, Plotkin H, Glorieux FH: Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003; 111: 1030-1036. (Pubitemid 36542617)
14. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML: Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003; 111: 573-578. (Pubitemid 36330714)
15. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC: Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20: 977-986. (Pubitemid 40712822)
16. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, for the HORIZON Recurrent Fracture Trial: Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-1809. (Pubitemid 350044800)
17. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-661. (Pubitemid 34815869)
18. Hogler W, Yap F, Little D, Ambler G, Mc- Quade M, Cowell CT: Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004; 145: 701-704. (Pubitemid 39440954)
19. Munns CF, Rajab MJ, Hong J, Briody J, Högler W, McQuade M, Little DG, Cowell CT: Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 2007; 41: 366-370. (Pubitemid 47199149)
20. Glorieux FH, Bishop N, Bober M, Brain CE, Devogelaer J, Fekete G, Forin V, Hopkin RJ, Kaitila I, Lee B, Lorenc R, Mahan JD, McCallister JA, Pettifor JM, Plotkin H, Rauch F, Salusky IB, Shaw N, Showalter L, Steelman JW, Steiner R, Tan M, Zhou W, Bucci-Rechtweg C: Intravenous zoledronic acid compared to intravenous pamidronate in children with severe osteogenesis imperfecta. Calcif Tissue Int 2008; 82:S85.
21. Johannesen J, Briody J, McQuade M, Little DG, Cowell CT, Munns CF: Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg- Calve-Perthes disease. Bone 2009; 45: 898-902.
22. Panigrahi I, Das RR, Sharda S, Marwaha RK, Khandelwal N: Response to zolendronic acid in children with type III osteogenesis imperfecta. J Bone Miner Metab 2010; 28: 451-455.
23. Pere A: Comparison of two methods for transforming height and weight to normality. Ann Hum Biol 2000; 27: 35-45. (Pubitemid 30049455)
24. Sorva R, Lankinen S, Tolppanen EM, Perheentupa J: Variation of growth in height and weight of children. II. After infancy. Acta Paediatr Scand 1990; 79: 498-506. (Pubitemid 20185309)
25. Valta H, Makitie O, Ronnholm K, Jalanko H: Bone health in children and adolescents after renal transplantation. J Bone Miner Res 2009; 24: 1699-1708.
26. Makitie O, Doria AS, Henriques F, Cole WG, Compeyrot S, Silverman E, Laxer R, Daneman A, Sochett EB: Radiographic vertebral morphology: a diagnostic tool in pediatric osteoporosis. J Pediatr 2005; 146: 395-401. (Pubitemid 40341752)
27. Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH: Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 2006; 39: 901-906. (Pubitemid 44311714)
28. Land C, Rauch F, Travers R, Glorieux FH: Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone 2007; 40: 638-644. (Pubitemid 46187230)
29. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441. (Pubitemid 32402100)
30. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR: HORIZON Pivotal Fracture Trial: once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822. (Pubitemid 46698462)
31. Rauch F, Munns CF, Land C, Cheung M, Glorieux FH: Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 2009; 24: 1282-1289.